Article
Dr. Jack Cush reviews more than a dozen news, journal articles and RNL highlights from this past week on RheumNow.com.
All News
Article
Recent reports have suggested a rising and unrecognized number of patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) compared to rheumatoid arthritis (RA).
Article
The Lupus Research Alliance and its clinical research affiliate Lupus Therapeutics today announced the launch of the Lupus Landmark Study, a groundbreaking observational research study to accelerate the development of personalized treatments for people living with lupus.
Article
A study of adults aged 45-85 yrs shows that knee osteoarthritis (OA) is an independent risk factor for falls, suggesting a greater need for awareness and prevention.
Article
Multinational metanalyses of data between 1989 and 2022 shows that NSAID prescriptions have decreased over time, and differs according to geographical locations.
Dr. John Cush
Tweet
Bone marrow edema was found in healthy individuals, Denis Poddubnyy #RNL2023 @RheumNow https://t.co/1n6E2QuGut https://t.co/y9Zzw6rdqN
Dr. John Cush
Tweet
What to look for( MRI ), Denis Poddubnyy #RNL2023 @RheumNow
STIR: inflammation
T1 erosion, fatty changes
VIBE: erosion https://t.co/enHned1acr
Dr. John Cush
Tweet
FRAX Tool is Suboptimal in Predicting Osteoporosis Fracture Risk in Younger Post-menopausal Women
https://t.co/oNTKZXSrzn https://t.co/OlbCuSuLlo
Dr. John Cush
Tweet
In the UK, MHRA has somewhat softened its warnings on Febuxostat use in gout - stating use caution if considering Febuxostat in patients with a prior history of major cardiovascular disease; esp w/ high urate and tophi burden or starting ULT https://t.co/y0KhXtgzzG https://t.co/5ZlE0XK8qx
Dr. John Cush
Tweet
The Burden of Chronic Pain in US Adults (2019-2020)
Analysis of National Health Interview Survey data shows that the incidence of chronic pain in the USA is high compared with other chronic diseases.
https://t.co/mH6Zb3i3Vw https://t.co/PWI8R6mKJR
Dr. John Cush
Tweet
J&J lawsuit against Amgen (Nov 2022) over Amgens biosimilar of Stelara has been settled (terms undisclosed) such that the Amgen biosimilar cannot be US marketed until 1/1/2025. Stelaras 2022 revenue was $9.7 billion https://t.co/NVgBsBNxk1 https://t.co/Fj8rn05RW0
Dr. John Cush
Tweet
Women’s health research lacks funding – these charts show how -- Nature has published a very slick/graphical representation of the deficient research funding (US NIH & UK UK Medical Research Council) of diseases affecting women. https://t.co/hJ8DzKxHeW https://t.co/aHoQTKOlRF
Dr. John Cush
Tweet
With all the new adalimumab biosimilars happening in 2023, where's the pen? Now the FDA has approved an ADA biosimilar, Cyltezo, Autoinjector Pen! https://t.co/yyyPa9d2Ye https://t.co/MuAnfJ0DsB
Dr. John Cush
Tweet
A call for the NIH to address disparities in women’s health research funding. In 1993 Congress mandated NIH include women/minorities in clinical trials. But 30 yrs later, only 11% of NIH budget went to womens diseases https://t.co/8yzUTD1Ufq https://t.co/27W6MnRCFx
Dr. John Cush
Tweet
Retrospective cross-sectional EMR study from Israel compared GI Dz in 18,598 FM pts vs 36,985 controls. FM significantly assoc w/ IBS (OR 4.61), GERD (OR 2.62), PUD (OR 2.13), celiac Dz(OR 2.08), IBD ; But not w/ GI malignancies https://t.co/mpLb3rE0CB https://t.co/mySSXC5sjA
Dr. John Cush
Tweet
SLE & dsDNA: 3,484 SLE pts (over 37,582 visits) - 29.5% had persistently dsDNA+ & 34% had fluctuating dsDNA.results & both assoc w/ SLE flares (HR 1.56 & 1.46). Doubling of dsDNA assoc w/ 33-36% increased risk of flare (p=0.009) https://t.co/quVlHrfSl3 https://t.co/DkD3h1wV6w
Dr. John Cush
Tweet
Dennis Poddubnyy #RNL2023
MRI sequences for axSpA:
Semi-coronal- T1 weighted, T2 STIR, T1 weighted w fat suppression
Semi-axial- T2 STIR
@RheumNow https://t.co/j119qQ0alv https://t.co/pVRO6SfiaI
Dr. John Cush
Tweet
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS
- it works but is it different from existing IL-17i?
- appears to work well in TNFi-inadequate responders
- are TNFi-IR pts immunologically different?
#RNL2023 https://t.co/bHboX3Xz6M https://t.co/kCa9MbFdxs
Dr. John Cush
Tweet
A short review from Dr. Deodhar for axSpA at #RNL2023
*prevalence is increasing
*remember the "3,4,5 rule" for MRI eval
*IL17 appear to be as good as TNFi
*may not need XR monitoring
*time will tell if IL17Fi will improve outcomes
https://t.co/fNhZZBmgaS https://t.co/g0g7e3Napl
Dr. John Cush
Tweet
ICYMI: Spondyloarthritis Innovations
https://t.co/N7AHcRIwcG https://t.co/eAgdiGTawz
